chrisvoncsefalvay/vaers-outcomes huggingface dataset:
When the nurse gave me the injection I felt the normal 'prick' and then at the end I got a split second worth of pain that I would rate as a '5 out of 10'.  So it was sore for a couple of days, and I thought it would go away, but now a month later, it is still not going away and with regular movement such as raising my arm above my head or reach out it really hurts. I am using motrin but as soon as I stop it resumes.
A report has been received from a Health Professional concerning an 11 year old, Female subject, who had been receiving Nasal FLUMIST (INTRANASAL). FLUMIST (INTRANASAL) started on 28-Oct-2014. Multiple patients received a half dose of FLUMIST which started on 28-Oct-2014. The outcome of the event of MULTIPLE PATIENTS RECEIVED A HALF DOSE OF FLUMIST is unknown. The report was considered to be non-serious.
Patient experienced chills, aches and unable to get out of bed for 2 days post injection. She also had a sore throat, and large swollen area around injection site with itching. This all started the day after the injection and the itching is still occuring a week later (although much more tolerable). Patient is in a long term care facility.
pt had severe vomiting x 12hr stopped suddenly & pt felt better after 3AM 10AUG96;
pt w/URI, no hx of fever given #3DTP/HIB & 1 hr p/vax  pt found having sz; temp on arrival to clinic 20 mins p/sz, t103.5; MD felt febrile seizure related to URI & fever & not vax;
Extreme pain from injection site down Left arm to fingers with "tightness and inability to move my arm" Radiated across scapula and into neck. Reports headache and nausea. Brief syncopal episode upon return from bathroom. 01/15/21 reports joint pain in bilateral knees, reoccurrence of left arm pain in the evening. Reports resolution of all symptoms by morning of 01/16/21.
p/ pt recv vax approx 22days later pt exp breakthrough chickenpox w/approx 20 lesions
318 patients received dose from vials beyond 30-day use by date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (318 patients received dose from vials beyond 30-day use by date) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (318 patients received dose from vials beyond 30-day use by date). On 11-Jun-2021, EXPIRED PRODUCT ADMINISTERED (318 patients received dose from vials beyond 30-day use by date) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were provided. Date of refrigeration of vaccine was 7th May 2021
Information has been received from a consumer concerning a 12 year old male who on an unknown date was vaccinated with MMR II (Enders-Edmonston, Jeryl Lynn, Wistar RA 27/3). The consumer reported that the patient developed autism after getting MMR II (Enders-Edmonston, Jeryl Lynn, Wistar RA 27/3). The caller believes it was "overnight." Caller reported "woman in a parent group mentioned everyone she talked to whose kids have autism claimed it happened overnight after they got MMR II (Enders-Edmonston, Jeryl Lynn, Wistar RA 27/3). There was no product quality complaint. Upon internal review, autism was determined to be an other important medical event. This is one of two reports received from the same source. No further information is expected.
This spontaneous report as received from a registered nurse refers to multiple unspecified patients of unknown age and gender. No medical history, concurrent conditions and concomitant medications were reported. On unknown dates, mulitple unspecified patients were vaccinated with COMVAX, lot # J013884, expiration date: 19-AUG-2016, (dose, administration route and site were not reported) after it was exposed to a supported temperature excursion of 32.9F for 2 hours and 45 minutes. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Medication was constituted according to labeling, 0.5ml of medication was administered to patient instead of the recommended 0.3ml. Error was not identified until after the 15 minute waiting period post vaccine was administered and the patient left the office. No adverse reaction was experienced by patient during the waiting period.
Maya began to feel very dizzy and had a headache starting about 12hrs after the vaccines were given. There was no fever, stiff neck, or nausea. She was referred to the ER for evaluation but left without being seen due to long wait. Evaluation in my office the next day - everything ok.
Eyes felt itchy after dose #1, knees and elbows itchy after dose #3. Hives to trunk and limbs after dose #4, No airway involvement. Symptoms improved with topical BENADRYL cream and 50mg oral dose x one time. Completely resolved after 36 hours.
injuries resulting from Zostavax use: Herpes Zoster; Herpes Zoster; products liability - defective design; manufacturing defect; Information has been received from a lawyer regarding a case in litigation concerning a currently 76 years old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not provided.  The patient was prescribed the Zoster Vaccine Live (ZOSTAVAX) vaccine by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 14-JUL-2015, the patient was vaccinated with zoster vaccine live(ZOSTAVAX) (dose, route of administration, anatomical location, lot#, expiration date were unknown) by a pharmacist. On an unknown date, the patient experienced injuries resulting from zoster vaccine live(ZOSTAVAX) use: herpes zoster and was treated at clinic. The reporter also claimed the product's liability - defective design; manufacturing defect. The outcome of events was unknown. The reporter considered the events to be related to Zoster Vaccine Live (ZOSTAVAX).
Diffuse vesicular rash - confirmed chickenpox, treated with Valtrex 1g PO Q12h x5 days.  Now with vaccinial disease.
Covid Arm Large red lesion at vaccination site Became very itchy Took antihistamine  Applied steroid creams and Benadryl Cream - nothing helped. As of September 9, 2021 arm isno longer itchy but still red
Area of vaccine site was red and was about 2" in diameter. Hard to tell if the area was hot since whole arm was warm. The site did not seem warmer than the rest of the arm.
Syncopal episode s/p vaccine administration. Site EMS assessed patient and performed vital signs. Monitored patient until  arrived. transported to  Hospital.
I started having runny nose, sniffles and burning like I was catching a cold. I took the at home COVID-19 home test on July 12, 2022. It was positive. The next day it was worse, I was real tired and felt overall horrible. My fever was 101.3. Yesterday afternoon I had my first dose of PAXLOVID and this morning when I woke up my temperature was 98.3. I have begun to feel better and better. I have just a hint of nasal running. I have not completely recovered but I feel by tomorrow I will feel 100%.
Sense of taste is severely affected. I can smell, but foods either have little to no flavor or they seem to be spoiled. i can taste certain things, but the flavor is off.
9-23-13 client reports by TC that on 9-14-13 she started with rash armpit (L). Rash itchy and spread down arm and rest of body. No other s/s. Referred to PMD 9-26-13 TC to client states provider seen, rash may be r/t Tdap - Rx for topical tx, not filled. Planned to get 2nd opinion, to call me with outcome, hasn't complied.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in an unspecified number of adult patients who received SHINGRIX for prophylaxis. On an unknown date, the patient received SHINGRIX. On an unknown date, unknown after receiving SHINGRIX, the patient experienced injection site pain and injection site rash. On an unknown date, the outcome of the injection site pain and injection site rash were unknown. It was unknown if the reporter considered the injection site pain and injection site rash to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not applicable for this report. The age group was not reported but it was selected as adult as per the vaccine indication. A pharmacist reported a few patients experienced injection site pain and injection site rash after the administration of SHINGRIX. The reporter consented to follow up. This is 5 of the 5 link cases, reported by same reporter. Sender's Comments:  US-GLAXOSMITHKLINE-US2020201572:same reporter US-GLAXOSMITHKLINE-US2020201575:same reporter US-GLAXOSMITHKLINE-US2020201576:same reporter US-GLAXOSMITHKLINE-US2020AMR202100:same reporter
Information has been received from a woman in a medical office concerning a 5 year old Caucasian female pt with no allergies and no past medical history who on 11FEB1998 was vaccinated in the right arm with a first dose of varicella virus vaccine live. There was no illness at the time of vaccination.  There was no concomitant medication. Subsequently, the patient was "exposed to disease (varicella virus vaccine live). On 13JAN2003, the patient "came down with disease" . Medial attention was not sought and laboratory testes were not performed. Subsequently,the patient recovered. The reporter also mentioned three other patients who had similar experiences following vaccination with varicella virus vaccine live. Additional information is not expected.
2 months apart; Room temperature; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 10-Aug-2021 and was forwarded to the company on 10-Aug-2021.    This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2 months apart) and PRODUCT STORAGE ERROR (Room temperature) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2 months apart) and PRODUCT STORAGE ERROR (Room temperature). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2 months apart) and PRODUCT STORAGE ERROR (Room temperature) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. The treatment information was unknown.; Sender's Comments: This report refers to a case of medication error, Inappropriate schedule of product administration and  Product storage error for 2nd dose of Covid 19/mRNA-1273 vaccine (lot number/batch number unknown) with no associated adverse event reported.
First day after shot had red quarter size rash/redness. Second/Third day rash/redness baseball size, forth/fifth day top of shoulder to elbow rash/redness hot to touch lasted for two/three days. Told to take Tylenol, week later redness/rash went away.
with in 30 seconds to 1min of administering both vaccines the patients head went back and had shook for about 10 to 15 seconds, patient came out of it and asked if he had been asleep.  EMS was called. patient was pale sweatin and nausea as well and light headed. No problems breathing or rash. EMS advised to keep eye on patient until someone arrived.
1. Burning skin sensation in my arm below the shot area that extends up to the wrist, the area is very cold.  The shot area is hot.  Hand inflammation making it difficult to close it (hilt).  Not much arm strength, difficult to hold heavy things. Decreases little by little 2. Felt the skin like when you have a cramp.  I touch it and don't felt much sensation from shoulder area up to the wrist.  Decreases each day. 3. Nausea 4. Sleepiness
Patient report vertigo beginning within 2 hours of second vaccine and has continued over 5 weeks, waxing and waning.  Patient reports 2 other family members getting the same vaccine, same location, and at the same time all had same vertigo symptom begin shortly after second vaccine.
Case number PHEH2014US003795 is an initial spontaneous report received from a consumer on 21 FEB 2014. This report refers to an 8-years -old female patient. Her medical history and concomitant medications were not reported. This patient under 18-years of age was vaccinated with FLUCELVAX 2013/2014 (batch number: not reported) at a dose of 0.5 ml intramuscularly on an unknown date. No adverse events were reported following the maladministration.  Following an internal review on 18 AUG 2014, a significant correction was done for the information received on 21 FEB 2014. The BPI labeling of the event "inappropriate age at vaccine administration " changed from listed to unlisted and added second indication as "drug used in unapproved population".
Patient started with headache, dizziness, blurred vision, nausea and vomiting which she went to an urgent care facility on 10/18.   On 10/19 she presented to an outside ER for the same symptoms, had a negative head CT and was sent home with antibiotics for a suspected UTI and meclizine for suspected vertigo.   On 10/20 she returned to that same ER with no improvement in symptoms, she experienced a seizure in their ER and Head CTa showed near complete thrombosis of superior sagittal sinus, with acute parasagittal frontal parenchymal and subarachnoid hemorrhage.   Patient arrived at our facility.
Mom called 1/2 hr p/shot recvd & said pt was "shaking" all over, had no temp; stated pt had hx of seizures & had forgotten to mention it; per MD mom gave Phenobarb & take to ER if necessary; pt to ER t104 given sponge bath;
Pain in arm and pain in thumb; This case was reported by a consumer via call center representative and described the occurrence of pain in extremity in a 72-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   In October 2021, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On an unknown date, an unknown time after receiving Shingrix, the patient experienced pain in extremity. On an unknown date, the outcome of the pain in extremity was not recovered/not resolved.   It was unknown if the reporter considered the pain in extremity to be related to Shingrix.  Additional details were reported as follows: The patient reported that he had received second dose of Shingrix about one month ago and immediately experienced pain in the injected arm. Also a month later he also experienced pain in thumb of same hand. Both events still exist. The reporter did not consent to follow up.
12 x 9 cm area of induration, heat, redness, pain at injection site.
PATIENT DEVELOPED A SMALL RED RASH WITH A SMALL AMOUNT OF PAIN STILL PRESENT 6 WEEKS AFTER IMMUNIZATION. PATIENT SAW HER DOCTOR, DOCTOR RECOMMENDED WAMR COMPRESSES AND BENADRYL FOR THE TIME BEING.
fever of 104 began 1 1/2hrs p/vax fever lasted x2 days; pt was taken to ER tx w/APAP & children's motrin
Oct 11th, right eye had floaters. Oct 12th, right eye flashes. Oct 14th, right eye floaters, flashes, and cloudiness. Oct 16th, right eye small constant black spot in the lower left hand corner of the visual spectrum. Oct 17th, right eye went completely blind. Went to the ER, and they performed an ultrasound, this showed that there had been a retinal detachment. Oct 18th, saw an ophthalmologist and the retina detachment was confirmed. Later that day, I saw a Retinal Specialist, the Retinal Detachment was confirmed along with there being enough of a tear that fluid had enter into the macular part of the eye. Surgery has been scheduled.
pt recv vax & later that day  "felt bad", & devel inject site rxn with redness and swelling.
Vaccine was given in left arm.  She is having pain, redness, itching and fever to top of left arm.
Impotency; Diarrhea; Fever; Chills; Headache; Fatigue; This is a spontaneous report from a contactable consumer (patient). A male patient of unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EWO167; Expiration Date: Aug2021), via an unspecified route of administration on an unspecified date as unknown, single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient reported side effects with the vaccine. On an unspecified date, the patient had impotency, diarrhea, fever, chills, headache, and fatigue. The outcome of the events was unknown.
11-3-13 high temp chills for days which caused a urinary problem and emergency ER 11-8-13 catheter had to be put in (11-14-13) hospitalized 11-14 - 11-16-2013 continue now with a urologist 11-19 to present, now not able to urinate like he should - more doctoring ahead.
Infant had vaccines at 9:00 am. At 12:00 PM, started screaming, mother unable to console. Screamed on and off x 3-4 hrs. Temp developed in the afternoon of 104.2 rectally. Has been given .8 dropper full of infant Tylenol every 6 hrs and cooling baths. Today temp is 102. No further screaming. Eating well.
196 patients received 0.25mL of Bivalent Moderna Covid-19 Vaccine; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of UNDERDOSE (196 patients received 0.25mL of Bivalent Moderna Covid-19 Vaccine) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced UNDERDOSE (196 patients received 0.25mL of Bivalent Moderna Covid-19 Vaccine) and NO ADVERSE EVENT (No adverse event). At the time of the report, UNDERDOSE (196 patients received 0.25mL of Bivalent Moderna Covid-19 Vaccine) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for UNDERDOSE (196 patients received 0.25mL of Bivalent Moderna Covid-19 Vaccine).    No concomitant drug information was provided.  It was unknown if the patient had received any other vaccine 4 weeks prior to COVID-19 vaccine.  No treatment drug information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-689916 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 27-Dec-2022: Follow-up received wherein age group and I narrative updated.; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-689916:Master case
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. On 12-MAY-2014 the patient was vaccinated intramuscularly with a 0.5 ml one dose of improperly stored PNEUMOVAX 23 (lot number J004080, expiration date 22-AUG-2014). No adverse effect reported. Additional information has been requested.
Extreme nausea, non stop throwing up, was about to pass out. Ended up in the hospital with a 101.5 fever, low blood pressure, elevated heart rate   Immediately after getting the vaccine I felt very nauseas and dizzy as well
Provider ordered Hep A and MENACTRA given by MA. Provider indicated after given that not needed. Patient had already been immunized.
(L) arm deltoid area injection site swelling/redness warm touch c/o painful after received DTaP/IPV
Large indurated, erythematous area on arm with itching and 3 small blisters.  Grew over the past week and is still present.  Vaccine site is a pale purple and about 2 cm in circumference.  Distally the erythema and induration extends 5 cm and is 4 cm wide.  The blisters are now dry.  Hot to touch.    Additionally initially for the first 3 days, severe headache and stiff neck, only on the left side (same as vaccine).
Pain, stiffness, and inflammation of muscles began within a few hours of vaccination. Unlike the first shot, the inflammation and stiffness didn't completely go away. Within a few days, the left hand became affected also, with the center two finger joints painful and difficult to move. Three months later, this is still going on. Severe dry eye, related to autoimmune diseases, became much worse. The muscle pain, weakness and inflammation are concerning because of the history of dermatomyositis.
pt recv vax 4SEP98 & sometime p/vax pt exp swollen lt arm from shoulder to elbow;reportedly the pt hosp;
This is a spontaneous report from a non-contactable nurse via a Pfizer sales representative. A patient of unspecified age ethnicity and gender received PREVNAR 13, via an unspecified route of administration, on an unspecified date, at single dose, for immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced arm redness on an unspecified date with outcome of unknown. No follow-up attempts possible. No further information expected.
3inches of swelling in arm; Arm began to ache dully every day/ sharp in the arm again; The pain is causing them to sleep poorly; This spontaneous case was reported by an other health care professional and describes the occurrence of PERIPHERAL SWELLING (3inches of swelling in arm), PAIN IN EXTREMITY (Arm began to ache dully every day/ sharp in the arm again) and INSOMNIA (The pain is causing them to sleep poorly) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Jan-2021, the patient experienced PAIN IN EXTREMITY (Arm began to ache dully every day/ sharp in the arm again) and INSOMNIA (The pain is causing them to sleep poorly). On an unknown date, the patient experienced PERIPHERAL SWELLING (3inches of swelling in arm). At the time of the report, PERIPHERAL SWELLING (3inches of swelling in arm), PAIN IN EXTREMITY (Arm began to ache dully every day/ sharp in the arm again) and INSOMNIA (The pain is causing them to sleep poorly) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided. Treatment medications were unknown. Action taken with mRNA-1273 in response to the events was not applicable.
Pt recvd 3 doses of Engerix-B in 1988 & titer was no checked in 1988; 9JAN92 titer was tested & a neg result was obtained; pt was considered to be a non-responder;
tired and weak for a long time and can't think good. I can't go out. I can't look at the cars when I go out. It messed up my brain. With my psych meds. They are crazy in the zoo and got me sick for a long time. I wish I never go the shot.